Latest Stock Buy or Sell? Make More Informed Decisions!
Today, Alex Ruus and Bryn Talkington commented about whether JEPQ-Q, PARA-Q, PYPL-Q, ABBV-N, ROKU-Q, META-Q, AMZN-Q, MOZ-T, BIR-T, RIO-N, ATH-T, PPL-T, GOOG-Q, INTC-Q, CVE-T, FLY-X, WELL-T, CFP-T, ENB-T, FRU-T, SU-T, TOU-T, PIF-T are stocks to buy or sell.
- Page 2/3
- Next Page
DON'T BUY
HOLD
Their last two quarters have frustrated her. She blames management who two quarters ago said they would focus less on growing new users, but rather increasing revenue on their user base. An activist could come in. She's hanging on, but running out of patience. She's hanging on because their Venmo is so interesting.
0
COMMENT
July was the best month in a year. The Fed's remarks this week were a soft pivot that the market liked. MSFT, Google and Amazon reported this week and missed topped and bottom lines. Yet, stocks went up. We haven't seen the capitulative flush in markets to bottom, but it has happened in tech, so he prefers tech going forward. He prefers oil stocks. Also, the 10-year yield was moving up, but is now declining. He is cautiously optimistic.
BUY
Healthcare is his favourite defensive sector. AbbVie needs to provide clear guidance about the erosion curve in Humira, its top drug (that will go off-patent next year). A popular drug going generic isn't necessarily a death sentence for the stock. He thinks management can pull this off. Sales declined only slightly, despite a 40% drop in Humira. Today, they announced a $2.2 billion settlement in opiod litigation (the opiod epidemic) which removes that overhang. It's probably a pretty good buy here.
